APAC Acute Myeloid Leukemia (AML) Treatment Market by Type and Geography - Forecast and Analysis 2022-2026

Published: Feb 2022 Pages: 120 SKU: IRTNTR72532

The acute myeloid leukemia (AML) treatment market share in APAC is expected to increase by USD 277.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.83%.

This acute myeloid leukemia (AML) treatment market in APAC research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers acute myeloid leukemia (AML) treatment market in APAC segmentation by type (chemotherapy, stem cell transplantation, and others) and geography (China, Japan, India, and Rest of APAC). The acute myeloid leukemia (AML) treatment market in APAC report also offers information on several market vendors, including AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. among others.

What will the Acute Myeloid Leukemia (AML) Treatment Market Size in APAC be During the Forecast Period?

Download the Free Report Sample to Unlock the Acute Myeloid Leukemia (AML) Treatment Market Size in APAC for the Forecast Period and Other Important Statistics

 

Acute Myeloid Leukemia (AML) Treatment Market in APAC: Key Drivers, Trends, and Challenges

The high incidence of acute myeloid leukemia is notably driving the acute myeloid leukemia (AML) treatment market growth in APAC, although factors such as lack of adequate healthcare infrastructure in developing nations may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the acute myeloid leukemia (AML) treatment industry in APAC. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Acute Myeloid Leukemia (AML) Treatment Market Driver in APAC

The high incidence of acute myeloid leukemia is one of the key drivers supporting the acute myeloid leukemia (AML) treatment market growth in APAC. For instance, the highest incidence of leukemia was estimated in Australia and New Zealand. The estimated number of new cases in Australia was 4,903 in 2021. Each year, in New Zealand, around 700 adults and 40 children are diagnosed with leukemia. Similarly, according to the Indian Council of Medical Research, the annual incidence of AML is 2-3 per 100,000, more in the age above 65. Moreover, China will witness 14,400 diagnosed incident cases of acute lymphocytic leukemia by 2029. AML treatment in China has been dominated by chemotherapy. Thus, the rising incidence of AML in the region will increase the adoption of treatment during the forecast period.

Key Acute Myeloid Leukemia (AML) Treatment Market Trend in APAC

CAR T-cell therapy for AML is another factor supporting the acute myeloid leukemia (AML) treatment market growth in APAC. It is one of the most promising ways of treating AML, which lets the patient's immune system fight leukemia. T cells are removed from the patient's blood and altered in the lab in this process. These cells are altered with the substance called chimeric antigen receptors (CARs) cells in the lab. It is then grown and infused into the patient's blood, where the leukemia cells act. Early clinical trials have shown some positive results. However, treatment has shown serious side effects in some cases on which doctors are currently working. Clinical approval of such treatment will cure AML very effectively during the forecast period. Such factors are driving the market growth.

Key Acute Myeloid Leukemia (AML) Treatment Market Challenge in APAC

The lack of adequate healthcare infrastructure in developing nations is one of the factors hindering the acute myeloid leukemia (AML) treatment market growth in APAC. Radiotherapy and chemotherapy devices require ample installation space due to their large size. There is a lack of adequate healthcare infrastructure in underdeveloped and emerging economies due to limited healthcare expenditure, which is one of the major factors restraining the adoption of cancer treatment. Only a limited number of healthcare institutions in underdeveloped and developing countries can use advanced radiotherapy systems for cancer treatment. This limits the number of radiotherapy and chemotherapy procedures despite their high demand. Such limitations are expected to impede acute myeloid leukemia (AML) treatment market growth in APAC during the forecast period.

This acute myeloid leukemia (AML) treatment market in APAC analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the acute myeloid leukemia (AML) treatment market growth in APAC as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the acute myeloid leukemia (AML) treatment market in APAC during the forecast period.

Who are the Major Acute Myeloid Leukemia (AML) Treatment Market Vendors in APAC?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • Agios Inc.
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

 

This statistical study of the acute myeloid leukemia (AML) treatment market in APAC encompasses successful business strategies deployed by the key vendors. The acute myeloid leukemia (AML) treatment market in APAC is fragmented and the vendors are deploying growth strategies such as focusing on product approvals, M&A, and product launches to compete in the market.

Product Insights and News

  • AbbVie Inc. - The company offers AML treatment for blood cancer patients.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The acute myeloid leukemia (AML) treatment market in APAC forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Acute Myeloid Leukemia (AML) Treatment Market in APAC Value Chain Analysis

Our report provides extensive information on the value chain analysis for the acute myeloid leukemia (AML) treatment market in APAC, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

  • Research and development (R&D) and drug discovery
  • Integration and product development
  • Manufacturing
  • Outbound logistics
  • Marketing and sales
  • Support activities
  • Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

 

Which are the Key Regions for Acute Myeloid Leukemia (AML) Treatment Market in APAC?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from China during the forecast period. China is the key market for acute myeloid leukemia (AML) treatment market in APAC. Market growth in this region will be slower than the growth of the market in India.

Personalized medicines have high demand in oncology therapy since conventional cancer drug therapies fail to achieve desired patient outcomes. This treatment will facilitate the acute myeloid leukemia (AML) treatment market growth in China over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 pandemic drastically affected China which, in turn, led to radical changes and disturbances in various medical procedures and treatments of AML. However, by January 2021, the number of cases in the country reduced, which led to the resumption of business activities. The resumption of various preclinical studies and pharmaceutical operations will drive the demand for AML treatment in China during the forecast period

What are the Revenue-generating Type Segments in the Acute Myeloid Leukemia (AML) Treatment Market in APAC?

To gain further insights on the market contribution of various segments Request for a FREE sample

The acute myeloid leukemia (AML) treatment market share growth in APAC by the chemotherapy segment will be significant during the forecast period. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body, which is very helpful in the treatment of AML as it is the cancer of the blood and bone marrow that spreads in all parts of the body. Therefore, the presence of many chemotherapy drugs for AML in APAC will drive market growth during the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the acute myeloid leukemia (AML) treatment market size in APAC and actionable market insights on post COVID-19 impact on each segment.

 

Acute Myeloid Leukemia (AML) Treatment Market Scope in APAC 

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 12.83%

Market growth 2022-2026

$ 277.03 million

Market structure

Fragmented

YoY growth (%)

12.56

Regional analysis

APAC

Performing market contribution

China at 40%

Key consumer countries

China, Japan, and India

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Acute Myeloid Leukemia (AML) Treatment Market in APAC Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive acute myeloid leukemia (AML) treatment market growth in APAC during the next five years
  • Precise estimation of the acute myeloid leukemia (AML) treatment market size in APAC and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the acute myeloid leukemia (AML) treatment industry in APAC 
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of acute myeloid leukemia (AML) treatment market vendors in APAC 

We can help! Our analysts can customize this report to meet your requirements. Get in touch

***1. Executive Summary                           

                **1.1 Market Overview

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

***2. Market Landscape                             

                **2.1 Market ecosystem             

                                *Exhibit 07:  Parent market

                                *Exhibit 08:  Market Characteristics

                **2.2 Value Chain Analysis          

                                *Exhibit 09:  Value chain analysis:  Pharmaceuticals

                                *2.2.1    Research and development (R&D) and drug discovery

                                *2.2.2    Integration and product development

                                *2.2.3    Manufacturing

                                *2.2.4    Outbound logistics

                                *2.2.5    Marketing and sales

                                *2.2.6    Support activities

                                *2.2.7    Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 10:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 11:  Market segments

                **3.3 Market size 2020 

                **3.4 Market outlook: Forecast for 2020 - 2025 

                                *3.4.1Estimating growth rates for emerging and high-growth markets

                                *3.4.2    Estimating growth rates for mature markets

                                *Exhibit 12:  Global - Market size and forecast 2021 - 2026 (million $)

                                *Exhibit 13:  Global market: Year-over-year growth 2021 - 2026 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 14:  Five forces analysis 2021 - 2026

                **4.2 Bargaining power of buyers           

                                *Exhibit 15: Bargaining power of the buyer

                **4.3 Bargaining power of suppliers       

                                *Exhibit 16: Bargaining power of the supplier

                **4.4 Threat of new entrants    

                                *Exhibit 17: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 18: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 19: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 20: Market condition - Five forces 2021

***5. Market Segmentation by Type

                **5.1 Market segments

                                *Exhibit 21: Type- Market share 2021-2026 (%)

                **5.2 Comparison by Type          

                                *Exhibit 22:  Comparison by Type

                **5.3 Chemotherapy - Market size and forecast 2021-2026           

                                *Exhibit 23:  Chemotherapy- Market size and forecast 2021-2026 ($ billion)

                                *Exhibit 24:  Chemotherapy- Year-over-year growth 2021-2026 (%)

                **5.4 Stem cell transplantation - Market size and forecast 2021-2026       

                                *Exhibit 25:  Stem cell transplantation - Market size and forecast 2021-2026 ($ billion)

                                *Exhibit 26:  Stem cell transplantation- Year-over-year growth 2021-2026 (%)

                **5.5 Others - Market size and forecast 2021-2026           

                                *Exhibit 27:  Others - Market size and forecast 2021-2026 ($ billion)

                                *Exhibit 28:  Others- Year-over-year growth 2021-2026 (%)

                **5.6 Market opportunity by Type          

                                *Exhibit 29:  Market opportunity by Type

***6. Customer landscape                         

                                *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                                *Exhibit 30:  Customer landscape

***7 Geographic Landscape

                **7.1 Geographic segmentation

                                *Exhibit 31:  Market share by geography 2021-2026 (%)

                **7.2 Geographic comparison   

                                *Exhibit 32:  Geographic comparison

                **7.3 China - Market size and forecast 2021-2026             

                                *Exhibit 33:  China - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 34:  China - Year-over-year growth 2021-2026 (%)

                **7.4 Japan - Market size and forecast 2021-2026             

                                *Exhibit 35:  Japan - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 36:  Japan - Year-over-year growth 2021-2026 (%)

                **7.5 India - Market size and forecast 2021-2026               

                                *Exhibit 37:  India - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 38:  India - Year-over-year growth 2021-2026 (%)

                **7.6 Rest of APAC - Market size and forecast 2021-2026               

                                *Exhibit 39:  Rest of APAC - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 40:  Rest of APAC - Year-over-year growth 2021-2026 (%)

                **7.7 Key leading countries        

                                *Exhibit 41:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 42:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1    High incidence of acute myeloid leukemia

                                *8.1.2    Advancements in pharmacology and molecular biology in APAC

                                *8.1.3    Rising adoption of generic drugs

                **8.2 Market challenges              

                                *8.2.1    Lack of adequate healthcare infrastructure in developing nations

                                *8.2.2    Complications related to chemotherapy

                                *8.2.3    High cost of treatment

                                *Exhibit 43:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1    CAR T-cell therapy for AML

                                *8.3.2    Approval of new treatment methods

                                *8.3.3    Increase in awareness programs

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 44:  Vendor landscape

                **9.2 Landscape disruption        

                                *Exhibit 45: ?Landscape disruption?

                                *Exhibit 46: Industry Risk

***10. Vendor Analysis               

                **10.1 Vendors Covered             

                                *Exhibit 47: Vendor Landscape

                **10.2 Market positioning of vendors    

                                *Exhibit 48: ?Market positioning of vendors?

                **10.3 AbbVie Inc.         

                                *Exhibit 49:  AbbVie Inc. - Overview

                                *Exhibit 50:  AbbVie Inc. - Business segments

                                *Exhibit 51:  AbbVie Inc. - Key offerings

                                *Exhibit 52:  AbbVie Inc. - Segment focus

                *10.4 Agios Inc.

                                *Exhibit 53:  Agios Inc.  - Overview

                                *Exhibit 54:  Agios Inc.  - Business segments

                                *Exhibit 55:  Agios Inc.  - Key offerings

                                *Exhibit 56:  Agios Inc.  - Segment focus

                **10.5 Astellas Pharma Inc.        

                                *Exhibit 57:  Astellas Pharma Inc. - Overview

                                *Exhibit 58:  Astellas Pharma Inc. - Product and service

                                *Exhibit 59:  Astellas Pharma Inc. - Key offerings

                **10.6 Bristol Myers Squibb Co.

                                *Exhibit 60:  Bristol Myers Squibb Co. - Overview

                                *Exhibit 61:  Bristol Myers Squibb Co. - Product and service

                                *Exhibit 62:  Bristol Myers Squibb Co. - Key offerings

                **10.7 Daiichi Sankyo Co. Ltd.   

                                *Exhibit 63:  Daiichi Sankyo Co. Ltd. - Overview

                                *Exhibit 64:  Daiichi Sankyo Co. Ltd. - Business segments

                                *Exhibit 65:  Daiichi Sankyo Co. Ltd. - Key offerings

                                *Exhibit 66:  Daiichi Sankyo Co. Ltd. - Segment focus

                *10.8 F. Hoffmann La Roche Ltd.

                               *Exhibit 67:  F. Hoffmann La Roche Ltd. - Overview         

                               *Exhibit 68:  F. Hoffmann La Roche Ltd. - Business segments      

                              *Exhibit 69:  F. Hoffmann La Roche Ltd. - Key offerings   

                              *Exhibit 70:  F. Hoffmann La Roche Ltd. - Segment focus

                **10.9 GlaxoSmithKline Plc         

                                *Exhibit 71:  GlaxoSmithKline Plc - Overview

                                *Exhibit 72:  GlaxoSmithKline Plc - Business segments

                                *Exhibit 73:  GlaxoSmithKline Plc - Key offerings

                                *Exhibit 74:  GlaxoSmithKline Plc - Segment focus

                **10.10 Novartis AG      

                                *Exhibit 75:  Novartis AG - Overview

                                *Exhibit 76:  Novartis AG - Business segments

                                *Exhibit 77:  Novartis AG - Key offerings

                                *Exhibit 78:  Novartis AG - Segment focus

                **10.11 Pfizer Inc.          

                                *Exhibit 79:  Pfizer Inc. - Overview

                                *Exhibit 90:  Pfizer Inc. - Product and service

                                *Exhibit 91:  Pfizer Inc. - Key News

                                *Exhibit 92:  Pfizer Inc. - Key offerings

                **10.12 Teva Pharmaceutical Industries Ltd.       

                                *Exhibit 93:  Teva Pharmaceutical Industries Ltd. - Overview

                                *Exhibit 94:  Teva Pharmaceutical Industries Ltd. - Business segments

                                *Exhibit 95:  Teva Pharmaceutical Industries Ltd. - Key offerings

                                *Exhibit 96:  Teva Pharmaceutical Industries Ltd. - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 ????Market definition

                                *11.1.2 ????Objectives

                                *11.1.3 ????Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 97: ?Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 98: ?Research Methodology

                                *Exhibit 99: ??Validation techniques employed for market sizing?

                                *Exhibit 100: ??Information sources

                **11.4 List of abbreviations        

                                *Exhibit 101: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

acute myeloid leukemia (aml) treatment market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis